Literature DB >> 23057479

Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era--an ecological study.

Andrea Salonia1, Matteo Ferrari, Antonino Saccà, Federico Pellucchi, Giulia Castagna, Maria Chiara Clementi, Rayan Matloob, Alberto Briganti, Patrizio Rigatti, Francesco Montorsi.   

Abstract

INTRODUCTION: It is common knowledge among researchers that erectile dysfunction (ED) is an important sentinel marker of cardiovascular and overall men's health. AIM: Determine whether the delay of time between ED onset and seeking medical help (DSH), considered as a proxy of awareness of the importance of ED for overall men's health, has shortened during the phosphodiesterase type 5 inhibitors (PDE5) era.
METHODS: Complete data from 619 patients seeking first medical help for new-onset ED as their primary disorder between July 2000 and July 2010 were analyzed (i.e., DSH, ED severity as defined by the International Index of Erectile Function-erectile function [IIEF-EF] domain score, patient's awareness of any PDE5, and Charlson Comorbidity Index [CCI]). Analysis of variance tested DSH throughout the 10-year time frame. Cox regression models tested the association between predictors and DSH. MAIN OUTCOME MEASURES: Assess if DSH has shortened throughout PDE5 era. Evaluate potential predictors of DSH.
RESULTS: Overall, mean DSH was 30.2 months (median 12.0; range 5-300 months). DSH shortened throughout the analyzed 10-year period (F = 1.918; P = 0.047), with a significant drop only from year 2009 (DSH up to year 2008 vs. from year 2009: 31.0 months [12.0] vs. 7.5 months [6.0], respectively; P < 0.001). Age, CCI, educational status, and ED severity did not significantly change over time. As a whole, 560 patients (90.5%) were aware of PDE5 at the time of their first office visit. PDE5 awareness emerged as an univarible and multivariable predictor of a shortened DSH. Conversely, DSH was not clearly associated with age, CCI, educational status, or ED severity.
CONCLUSIONS: Delay in seeking medical help in new-onset ED patients remained high over the PDE5 era, with a significant drop only from the year 2009. PDE5 awareness emerged as an independent predictor of shortening of this delay.
© 2012 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23057479     DOI: 10.1111/j.1743-6109.2012.02953.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  9 in total

1.  Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.

Authors:  W-K Tsai; B-P Jiann
Journal:  Int J Impot Res       Date:  2014-01-23       Impact factor: 2.896

2.  Modern utilization of penile prosthesis surgery: a national claim registry analysis.

Authors:  R L Segal; S B Camper; A L Burnett
Journal:  Int J Impot Res       Date:  2014-05-15       Impact factor: 2.896

3.  Trends in reported male sexual dysfunction over the past decade: an evolving landscape.

Authors:  Edoardo Pozzi; Paolo Capogrosso; Luca Boeri; Walter Cazzaniga; Rayan Matloob; Eugenio Ventimiglia; Davide Oreggia; Nicolò Schifano; Luigi Candela; Costantino Abbate; Francesco Montorsi; Andrea Salonia
Journal:  Int J Impot Res       Date:  2020-07-01       Impact factor: 2.896

Review 4.  Endocrine evaluation of erectile dysfunction.

Authors:  Andrea Sansone; Francesco Romanelli; Daniele Gianfrilli; Andrea Lenzi
Journal:  Endocrine       Date:  2014-04-06       Impact factor: 3.633

5.  Prevalence, correlates, attitude and treatment seeking of erectile dysfunction among type 2 diabetic Chinese men attending primary care outpatient clinics.

Authors:  Wai Hon Lo; Sau Nga Fu; Carlos King Ho Wong; Ee San Chen
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

6.  Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.

Authors:  Giovanni Corona; Carlo B Giorda; Domenico Cucinotta; Piero Guida; Elisa Nada
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

7.  Increasing access to erectile dysfunction treatment via pharmacies to improve healthcare provider visits and quality of life: Results from a prospective real-world observational study in the United Kingdom.

Authors:  Lauren J Lee; Terence A Maguire; Martine C Maculaitis; Birol Emir; Vicky W Li; Mara Jeffress; Jim Z Li; Kelly H Zou; Shaantanu S Donde; David Taylor
Journal:  Int J Clin Pract       Date:  2020-12-05       Impact factor: 2.503

Review 8.  Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons.

Authors:  James E Ferguson; Culley C Carson
Journal:  Arab J Urol       Date:  2013-09-18

9.  Help-seeking behavior for erectile dysfunction: a clinic-based survey in China.

Authors:  Kai Zhang; Wei Yu; Zhan-Ju He; Jie Jin
Journal:  Asian J Androl       Date:  2014 Jan-Feb       Impact factor: 3.285

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.